The combination of Tamoxifen and growth factor receptor kinase inhibitor (RKI) is also one of the main therapeutic approaches for Tamoxifen‐resistant breast cancer with overexpression of EGFR or HER‐2. This evidence concerns the gene EGFR and breast carcinoma.